Last reviewed · How we verify
NCT06775067
Incremental Dialysis Decision Model Based on Expert-Guided Machine Learning
trial in End-stage Renal Disease in 175 participants. Completed in 28 June 2024.
28 June 2024
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 175 |
| Start date | 12 April 2010 |
| Primary completion | 28 June 2024 |
| Estimated completion | 28 June 2024 |
| Sites | 1 location across China |
Conditions studied
- End-stage Renal Disease — all drugs for End-stage Renal Disease →
Sponsor
Huashan Hospital
Who can join
18 and older, any sex, with End-stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational prospective study combined clinical expert knowledge with machine learning to develop and validate a predictive model for incremental hemodialysis decision-making. The aim of the predictive model is to assist clinicians in developing individualized incremental dialysis treatment plans to optimize patient outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06775067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End-stage Renal Disease
Currently open trials in the same condition.
- NCT06755372 — The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Populati · recruiting
- NCT05473299 — Xeltis Hemodialysis Access Graft: aXess Pivotal Study · NA · active not recruiting
- NCT05154773 — Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication · NA · active not recruiting
- NCT03994497 — Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Rena · NA · recruiting
- NCT02728817 — Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation · NA · active not recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06775067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06775067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing